Tempus AI (NASDAQ:TEM) Price Target Raised to $85.00

Tempus AI (NASDAQ:TEM) had its target price lifted by analysts at HC Wainwright from $68.00 to $85.00 in a research report issued to clients and investors on Tuesday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright‘s price target points to a potential upside of 8.31% from the company’s current price.

A number of other equities analysts have also commented on TEM. Lake Street Capital lowered Tempus AI to a “hold” rating in a research note on Monday, July 20th. JPMorgan Chase & Co. increased their target price on Tempus AI from $45.00 to $70.00 and gave the company a “neutral” rating in a research note on Wednesday, October 14th. TD Cowen reaffirmed a “buy” rating on shares of Tempus AI in a report on Wednesday, July 15th. BTIG Research reaffirmed a “buy” rating and issued a $100.00 price target (up from $80.00) on shares of Tempus AI in a research report on Tuesday. Finally, Stifel Nicolaus cut their price target on Tempus AI from $60.00 to $50.00 and set a “hold” rating for the company in a report on Monday, August 3rd. Eleven analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $79.37.

Tempus AI Stock Performance

Shares of TEM opened at $78.48 on Tuesday. The firm has a market cap of $14.16 billion, a price-to-earnings ratio of -54.50 and a beta of 3.54. The company’s fifty day moving average is $70.80 and its 200-day moving average is $57.12. The company has a quick ratio of 3.16, a current ratio of 3.30 and a debt-to-equity ratio of 3.06. Tempus AI has a 12 month low of $40.77 and a 12 month high of $90.53.

Tempus AI (NASDAQ:TEM) last posted its earnings results on Monday, November 2nd. The company reported $0.07 earnings per share for the quarter, topping the consensus estimate of ($0.09) by $0.16. Tempus AI had a negative return on equity of 50.28% and a negative net margin of 17.77%. The firm had revenue of $411.54 million during the quarter, compared to analyst estimates of $409.39 million. During the same period in the previous year, the company earned ($0.46) EPS. The company’s revenue for the quarter was up 23.1% on a year-over-year basis. Equities analysts expect that Tempus AI will post -1.45 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CEO Ryan Fukushima sold 41,095 shares of the stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $49.61, for a total transaction of $2,038,722.95. Following the completion of the sale, the chief executive officer owned 562,463 shares in the company, valued at $27,903,789.43. This trade represents a 6.81% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Andrew Polovin sold 22,148 shares of Tempus AI stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $49.61, for a total transaction of $1,098,762.28. Following the completion of the transaction, the executive vice president owned 146,067 shares of the company’s stock, valued at $7,246,383.87. This trade represents a 13.17% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders have sold 1,256,777 shares of company stock valued at $86,356,352. 24.26% of the stock is owned by insiders.

Institutional Investors Weigh In On Tempus AI

Hedge funds have recently added to or reduced their stakes in the stock. Sumitomo Mitsui Trust Group Inc. increased its position in Tempus AI by 23.4% in the 1st quarter. Sumitomo Mitsui Trust Group Inc. now owns 4,326,313 shares of the company’s stock valued at $195,636,000 after acquiring an additional 821,490 shares in the last quarter. Amova Asset Management Americas Inc. raised its stake in shares of Tempus AI by 23.4% in the first quarter. Amova Asset Management Americas Inc. now owns 4,326,313 shares of the company’s stock worth $195,549,000 after acquiring an additional 821,490 shares during the last quarter. Eagle Health Investments LP acquired a new position in shares of Tempus AI during the first quarter worth approximately $11,588,000. Swiss National Bank lifted its position in shares of Tempus AI by 0.3% during the first quarter. Swiss National Bank now owns 183,500 shares of the company’s stock worth $8,298,000 after purchasing an additional 600 shares in the last quarter. Finally, Aristotle Atlantic Partners LLC acquired a new position in shares of Tempus AI during the first quarter worth approximately $6,179,000. Institutional investors own 24.22% of the company’s stock.

Tempus AI News Summary

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: Q3 earnings and revenue beat expectations. Tempus reported adjusted earnings of $0.07 per share versus the expected $0.09 loss, while revenue rose 23.1% year over year to $411.54 million, slightly above the $409.39 million consensus. The narrower loss and strong top-line growth were the primary catalysts for the stock’s advance. Tempus Reports Third Quarter 2026 Results
• Positive Sentiment: Management raised its 2026 revenue outlook. Tempus now expects approximately $1.60 billion to $1.605 billion in 2026 revenue and continues to target about $65 million in adjusted EBITDA. Investors were encouraged by growth in the Data and Applications segment, which expanded 33% and carries gross margins above 71%, as well as the company’s collaboration with Bristol Myers Squibb. Tempus 2026 Revenue Outlook
• Positive Sentiment: Analyst and trading signals improved. Needham raised its price target from $75 to $89 and maintained a Buy rating. Trading activity also showed elevated call-option demand, while Cathie Wood’s Ark Investment Management reportedly purchased about $11.2 million of TEM shares, adding to bullish sentiment.
• Neutral Sentiment: Analyst views remain mixed. UBS reiterated a Hold rating with an $80 price target, citing solid oncology execution but weaker hereditary testing. This suggests the earnings beat was encouraging, but some analysts remain cautious about the pace and quality of growth. Tempus UBS Rating
• Negative Sentiment: Personalis acquisition risks remain. Reports highlight potential challenges integrating Personalis, including execution complexity and the possibility that deal-related costs or operational disruption could weigh on future performance. Personalis Integration Risks

About Tempus AI

Tempus AI, Inc is a healthcare technology company that uses artificial intelligence and data analytics to support precision medicine. The company combines clinical, molecular and imaging data to help physicians make more informed treatment decisions and to help researchers and biopharmaceutical companies develop therapies.

Its offerings include genomic testing and analysis, such as tissue- and blood-based tests, as well as software tools designed to assist with clinical decision-making, patient matching for clinical trials and the management of healthcare data.